Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7331308 | 0.88 | AVPR2 (0.54) | PDCD1CD274AVPR2AVPR1A | |
| SCHEMBL7340964 | 0.88 | KCNJ5 (0.48) | KCNJ5KCNJ3ROCK2 | |
| SCHEMBL7340205 | 0.82 | AVPR2 (0.55) | AVPR2AVPR1A | |
| SCHEMBL7334954 | 0.80 | AVPR2 (0.43) | AVPR2KCNN4KCNA3AVPR1A | |
| SCHEMBL7331304 | 0.80 | KMT2A (0.48) | AVPR2KCNN4KCNA3AVPR1AROCK2 | |
| SCHEMBL8600947 | 0.79 | MAPT (0.43) | AVPR2MAPTHSD17B10 | |
| SCHEMBL8561675 | 0.78 | NAMPT (0.50) | KCNJ5KCNJ3AVPR1A | |
| SCHEMBL8562914 | 0.77 | AVPR2 (0.50) | AVPR2MAPTAVPR1A | |
| SCHEMBL8334028 | 0.76 | NAMPT (0.44) | KCNN4KCNA3AVPR1A | |
| SCHEMBL8556372 | 0.76 | KCNJ5 (0.51) | AVPR2KCNJ5KCNJ3AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5843952-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-12-01 | — | — | US | claimed |
| US-5854236-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-12-29 | — | — | US | disclosed |
| US-5843952-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| US-5834461-A | TREATING CONGESTIVE HEART FAILURE | AMERICAN CYANAMID COMPANY (US) | 1998-11-10 | — | — | US | disclosed |
| US-5786353-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| US-5760031-A | KIDNEY DISEASES | AMERICAN CYANAMID COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5747487-A | N-(4-((4,5-DIHYDRO-6H-THIAZOL(5,4-D)(1)BENZAZEPIN-6-YL) -CARBONYL)PHENYL)BENZAMIDES; DISEASES CHARATERIZED BY EXCESS RENAL ABSORPTION OF WATER, E.G. CONGESTIVE HEART DISEASE, HYERTENSION; OXYTOCIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5739128-A | ADMINISTERING FOR TREATMENT OF DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5736538-A | TREATS IN MAMMAL THE DISEASE CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER, IS CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, HYPONATREMIA, CORONARY AND RENAL VASOSPASM, CARDIAC ISCHEMIA, LIVER CIRRHOSIS AND BRAIN EDEMA | AMERICAN CYANAMID COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| US-5693635-A | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS RENAL ABSORPTION OF WATER; CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME | AMERICAN CYANAMID COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5686445-A | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| US-5512563-A | TREATING DISEASES CAUSED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-04-30 | — | — | US | disclosed |